Revance Therapeutics (RVNC) Misses Q1 EPS by 3c

Revance Therapeutics (NASDAQ: RVNC) reported Q1 EPS of ($0.94), $0.03 worse than the analyst estimate of ($0.91). Revenue for the quarter came in at $25.3 million versus the consensus estimate of $24.01 million.

For earnings history and earnings-related data on Revance Therapeutics (RVNC) click here.

You May Also Be Interested In

• SanDisk and Micron surge as Apple confirms memory price pass-through
• Kroger (KR) Reports In-Line Q1 EPS, Beats on Revenue; Offers FY27 EPS Guidance
• Air France-KLM (AF:FP) (AFLYY) PT Raised to EUR13.50 at UBS